05:04 PM EDT, 08/18/2025 (MT Newswires) -- Invivyd ( IVVD ) said Monday it has seen "clinically meaningful in vitro neutralization data" for Pemgarda against the XFG variant of SARS-CoV-2, the virus that causes COVID-19.

Pemgarda has been approved by the US Food and Drug Administration (FDA) for pre-exposure protective treatment of COVID-19 in some immunocompromised people, the company said.

Invivyd ( IVVD ) said results showing the neutralizing activity of Pemgarda against XFG and other viruses will be sent to the FDA soon.

The company's shares were rising nearly 5% in recent after-hours activity.